Literature DB >> 2320646

Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference.

J C Froehlich1, J Harts, L Lumeng, T K Li.   

Abstract

The effect of naloxone on voluntary ethanol intake was examined in rats which were selectively bred for oral ethanol preference (High Alcohol Drinking or HAD line). Rats of the HAD line were treated with naloxone in doses of 0.05-18.0 mg/kg b.wt. before access to water alone or to a free-choice between a 10% (v/v) ethanol solution and water. Naloxone suppressed water intake when water was presented as the sole source of fluid. In contrast, naloxone produced a dose-dependent decrease in ethanol consumption, without altering water intake, when rats were given a free-choice between the ethanol solution and water. Selective suppression of ethanol consumption by naloxone was not attributable to changes in blood ethanol concentrations or ethanol elimination rates following naloxone treatment. It appears that although naloxone may attenuate the positively reinforcing properties of both ethanol and water, ethanol drinking is a subset of consummatory behaviors that is particularly sensitive to opioid receptor blockade. The results suggest that activation of the endogenous opioid system may be an important mechanism which serves to maintain continued ethanol drinking.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2320646     DOI: 10.1016/0091-3057(90)90174-g

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  52 in total

Review 1.  The central opioid system in liver disease and its complications.

Authors:  C Yurdaydin
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

Review 2.  An experimental approach to understanding the genetic and neurobiological basis of alcoholism.

Authors:  T K Li; L Lumeng; W J McBride; J M Murphy
Journal:  Trans Am Clin Climatol Assoc       Date:  1993

Review 3.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

4.  Importance of delta opioid receptors in maintaining high alcohol drinking.

Authors:  J C Froehlich; M Zweifel; J Harts; L Lumeng; T K Li
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Reduced alcohol consumption in mice lacking preprodynorphin.

Authors:  Yuri A Blednov; Danielle Walker; Marni Martinez; R Adron Harris
Journal:  Alcohol       Date:  2006-10       Impact factor: 2.405

6.  Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone.

Authors:  Janice C Froehlich; Brett J Hausauer; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2013-07-22       Impact factor: 3.455

7.  A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.

Authors:  Nurulain T Zaveri; Paul V Marquez; Michael E Meyer; Willma E Polgar; Abdul Hamid; Kabirullah Lutfy
Journal:  Alcohol Clin Exp Res       Date:  2018-01-19       Impact factor: 3.455

8.  Effects of naltrexone on post-abstinence alcohol drinking in C57BL/6NCRL and DBA/2J mice.

Authors:  Arthur Tomie; Idu Azogu; Lei Yu
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-03-13       Impact factor: 5.067

9.  Consequence of long-term exposure to corticosterone or dexamethasone on ethanol consumption in the adrenalectomized rat, and the effect of type I and type II corticosteroid receptor antagonists.

Authors:  C Fahlke; E Hård; C J Eriksson; J A Engel; S Hansen
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

Review 10.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.